Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies

NCT03623087 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT03623087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03623087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies
Lead sponsor
The University of Hong Kong
Phase
Phase 3
Overall status
Unknown status
Start date
July 1, 2017
Completion date
June 30, 2020
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

natural killer/t-cell lymphoma, nasal and nasal-type, non-hodgkin t-cell lymphoma, non-hodgkin's lymphoma, relapsed